1. Introduction {#s0005}
===============

Celiac Disease (CD) is a chronic enteropathy elicited by gluten, a storage protein found in rye, barley, and wheat, in genetically susceptible individuals ([@b0100]). CD has a worldwide prevalence of 0.5%-1%. Recent *meta*-analysis study has reported the variable prevalence of CD in Asians (0.6%), North Americans (0.5%), South Americans (0.4%), and Europeans (0.8%) ([@b0260]). Interestingly, CD was found to be prevalent in 1.5% of Saudi children ([@b0040]). The actual prevalence of CD is seen to be variable among different regions in the kingdom. For example, the highest sero-positivity prevalence was reported in the central region with 3.2%, followed by the southwestern region with 2.1% and the lowest frequency of 1.8% was reported in the western region ([@b0045]). CD primarily damage the small intestinal tissues, although it shows broad clinical manifestations. According to Oslo classification, the clinical presentation of CD, could be either classical, non-classical, silent, latent or refractory among other specific subtypes ([@b0195]). Therefore, one of the main complications of CD is delayed diagnosis due to its clinical diversity ([@b0115]). Nevertheless, duodenal biopsy for small bowel villous atrophy and serological tests of anti-tTG antibodies, anti-endomysium antibodies (EmA), and deamidated gliadin peptide (DGP) antibodies are still considered as gold standard diagnostic tests for confirmation of CD ([@b0300]). Till date, CD treatment involves keeping patients on a strict gluten-free diet to reduce the symptoms, but not the histological manifestations ([@b0305]).

Like other autoimmune diseases, CD is also caused by the complex interactions between genetic, non-genetic factors and immune responses. Gluten consumption along with HLA and non-HLA predisposition alleles contributes to its complexity, thus making CD not just a multifactorial but polygenic disorder. Particularly, HLA-DQ2.5 and HLA-DQ8 haplotypes play a crucial role in stimulating the abnormal reaction in the gastrointestinal tract against gluten. In Saudi population, high risk HLA-DQ alleles were known to be prevalent in 52.7% of healthy children from Riyadh province ([@b0035]). Although, HLA genes can increase the risk of the disease, they are not sufficient for developing CD. For example, together HLA DQ2.5 and DQ8 alleles could only explain 25%-40% of the CD genetic risk ([@b0185]). This implies that, unknown non-HLA genes also largely contribute to the disease development. The introduction of Genome-wide association studies (GWAS) in CD patients, have helped in discovering the role of 56 non-HLA genetic loci in modifying the disease risk ([@b0145], [@b0285], [@b0080], [@b0280]). As per the current understanding, non-HLA genetic susceptibility loci only contributes 10% of the current CD risk ([@b0310]).

Although, GWAS provided a well-recognized knowledge about CD genetics, however most studies were carried out among Caucasians or Asians ([@b0135], [@b0140]). This necessitates us to look for genetic markers in other ethnic populations like Saudi Arabians who possess a unique genetic architecture due to the high consanguineous marriage backgrounds ([@b0035], [@b0050]). Furthermore, majority of the classical GWAS studies were carried out among sporadic cases and could not identify any causal genes. This highlights the need to study CD in rare familial cases to unveil the role of rare variants in genes that cannot be spotted by genome wide association studies conducted in sporadic cases. While common variants in CD are extensively studied through microarray-based genome wide genotyping, studying rare variants has only become feasible with next-generation sequencing approaches like whole exome sequencing (WES), which scans coding regions of the human genome. Therefore, owing to the limited scientific data available on familial aggregation of CD, this study was aimed to find the potential rare variant causal to CD in a Saudi Arabian family using a combination of whole exome sequencing and systems biology approaches.

2. Materials and methods {#s0010}
========================

2.1. Recruitment of CD family and sporadic cases {#s0015}
------------------------------------------------

The Saudi family with two CD affected siblings were referred to our Pediatric Gastroenterology clinic in King Abdulaziz University Hospital. Both these children met the standard diagnostic guidelines of the European Society for Pediatric Gastroenterology, Hepatology and Nutrition (ESPHGAN) for CD ([@b0150]). In brief, CD diagnosis included clinical examinations by pediatric gastroenterologists, intestinal endoscopy and serological test for tissue transglutaminase antibodies (anti-tTG). Multi-generation pedigree was drawn by geneticists after collecting the full family history. In order to validate the genetic findings of CD family, we have additionally recruited 100 sporadic CD cases, who were regularly followed up at our gastroenterology clinic since the time they were diagnosed. This study protocol was approved by the Research Ethics Committee, King Abdulaziz University Hospital, Jeddah (KAUH). The parental written informed consent were obtained after explaining them about our study protocol. Approximately 2.5--3 ml of venous blood samples from all the family members were collected in EDTA tubes and stored at −80 °C until genetic analysis was performed.

2.2. DNA extraction {#s0020}
-------------------

Genomic DNA was extracted and purified with QIAamp DNA blood Kit, following the manufacturer's instructions. DNA concentration and purity were measured by Nanodrop (ND-1000 UV--VIS) spectrophotometer.

2.3. WES analysis {#s0025}
-----------------

Genomic DNA (100 ng/µl; 260/280 ratio of 1.8--2.0) was used for preparing the library. The whole exome sequencing was performed on HiSeq2000 Next Generation Sequencer (Illumina, San Diego, CA). DNA shearing was done using Agilent Sure Select Target V6 Enrichment capture kit, reaching an optimal size-ranged fragments. The fragmented DNA were hybridized with ultra-long 120-mer biotinylated cRNA library baits. Library concentration and size were examined by capillary electrophoresis. Different adapters were integrated during enrichment, allowing the samples to be amplified for further sequencing. The sequencing reads (in FASTQ format) were aligned against the human genome reference sequence build 38 (GRCH38.p12) supported by BLAST (version 0.6.4d) for variant calling and annotation. The genome analysis toolkit (GATK) was used for downstream high quality variant calling ([@b0210]). The SAM tools suite was used to differentiate SNPs and short insertion/deletion in each read ([@b0060]). The read coverage was \~ 100×, representing 87% of the targeted region, as ([Fig. 1](#f0005){ref-type="fig"}).Fig. 1Workflow whole-exome sequencing; Phase I- Sample preparation; Phase II Sequence read mapping: Phase III Variant calling; Phase IV: Variants validation and Genotyping.

2.4. Variant filtering and candidate gene selection {#s0030}
---------------------------------------------------

CD candidate gene list was collected from different databases (NCBI, GWAS catalog, celiac gene panels) to verify their presence in the exome data of our patients. From the WES data, variants were retained if: (1) they passed the sequencing quality control (2) they were found in coding or regulatory sites (3) they had an allele frequency (MAF) of \< 1.5% in general populations, African population, East and south Asian population, (4) they had an allele frequency \< 1.49 × 10^−02^ based on the gnomAD database, (5) they are homozygote or compound heterozygotes showing an autosomal recessive inheritance pattern. Moreover, all genes with variants were filtered by their functional relevance to autoimmune diseases in general, and particularly to CD. Genes whose expression was reported in the small intestine or any related parts of the gastrointestinal system were considered potential to CD. The rare frequency of the filtered variants, was further verified in the WES data of 2379 healthy Saudi volunteers, hosted on Saudi Genome Project webserver (SHGP: <https://www.saudigenomeproject.org/en/>).

2.5. Sanger sequencing of candidate variant {#s0035}
-------------------------------------------

The potential WES-derived candidate variants were further confirmed through Sanger sequencing. For this purpose, we designed oligonucleotide specific primers using open source NCBI Primer Blast webserver ([@b0315]) with an average of 400--600 bp of target amplicon size. (supplementary Table 1). All the sequence reads were aligned and analyzed against reference mRNA ([ENST00000310396.10]{.ul}) sequence of CPED1 gene with BioEdit (<http://www.mbio.ncsu.edu/>) program. Mutation position was determined considering "A" of first ATG codon of the mRNA.

2.6. Computational analysis of candidate protein {#s0040}
------------------------------------------------

The human *CPED1* sequences (both nucleotide and amino acid) were aligned against *CPED1* sequence of 13 selected primates, with help of comparative genomic orthologue option available in Ensemble browser ([www.esembl.org]{.ul}) for examining whether the causative variant is located in a conserved sequence region. We also sought to explore the consequences of candidate rare variant on the protein structure by simulating its 3D structure through either *ab-initio* or homology modeling approaches, depending on the availability of experimentally solved structure ([@b0240]). Confidence of each model is quantified by the C-score based on (a) significance of threading template alignments, and (b) convergence parameters of the structure assembly simulations. The best protein selected by highest C-score was subjected to energy minimization by applying the structure to the gromacs-steepest descent energy minimization method using NOMAD-Ref web server ([@b0180]). Moreover, the energy minimized native model was entered into DUET software to build the mutated model and to predict variant impact on the protein stability ([@b0010]). In addition, backbone atoms variations among superimposed proteins both at whole structure and residue levels were analyzed by calculating their positional root mean square deviation (RMSD) values. RMSD cutoff score considered for complete structure alterations was \> 2.0 Å and for residue level it was \> 0.2 Å ([@b0015], [@b0205], [@b0165]). Finally, network analysis results of STRING v.9.1 webserver were used to identify the key pathways and gene networks based on known protein--protein interactions between the candidate proteins and other genes ([@b0110], [@b0255]).

3. Results {#s0045}
==========

3.1. Case presentation {#s0050}
----------------------

The proband III.1 (3 years) was born to unrelated parents with no family history for celiac disease ([Fig. 2](#f0010){ref-type="fig"}). With the introduction of formula milk, she developed gastrointestinal symptoms including severe abdominal pain, bloating and diarrhea. She also demonstrated other symptoms like mild osteoporosis, eczema, severe skin rash, short stature, weight loss and lack of appetite. Besides that, she was previously diagnosed with left congenital renal and ureter disease. Endoscopy test showed fissures on the folds and absence of intestinal villi and her tTG antibody screening confirmed that she is CD positive. Her younger sister III.2 (2 years) suffers from severe diarrhea, vomiting and abdominal bloating is triggered when solid food was introduced at six months of age. She was also put on gluten free diet. She has a normal weight chart and no further complications were reported. All symptoms disappeared after keeping both of them on gluten-free diet.Fig. 2Sanger sequencing analysis of CD Family. Probands are indicated by the (arrow). Exome sequenced individuals are indicated with an (\*) mark showing the electrophoretic trace for mutations of the *CPED1* gene. The probands are homozygous to the mutation in exons 2 (c.241 G/G). Both parents are heterozygous for the mutation (c.241 A/G).

3.2. Exome sequencing {#s0055}
---------------------

The terms 'variant' or 'mutation' represents each other in this manuscript. Exome data had an output of approximately 100 K of variants for each individual. Non-coding variants (downstream, upstream, intergenic and intronic variants) were excluded, except the regulatory region variants (3′-UTR and 5′-UTR). All data were filtered to exclude shared variants with MAF of \> 0.015 based on 1000 Genomes Project data. The exome data were screened for both homozygous and heterozygous mutations. In these patients, about 2600 unique and rare variants were detected in the form of missense, frameshift and regulatory region mutations ([Fig. 3](#f0015){ref-type="fig"}).Fig. 3The genetic variants yield of CD family. Yellow section indicates the whole variants generated from whole exome sequencing. Green section indicates known variants with MAF \> 1.5%. Orange section indicates variants with MAF \< 1.5%. Blue section indicates final filtered variants. Note: Filtering criteria for variants: exonic, unknown or extremely rare (MAF = \<0.015%).

All the filtered variants were further segregated based on their functional annotations to CD, or other gastrointestinal disease with known autoimmune background. The final list consisted of 16 pathogenic variants (8 missense, 2 frameshift and 6 UTR), spanning 9 genes located on different chromosomes: 7,12,14,18,19 and 22. All these genes were known to have a putative functional relationship with inflammatory responses or autoimmune diseases ([Table 1](#t0005){ref-type="table"}, [Table 2](#t0010){ref-type="table"}). Among these 16 variants, a homozygous missense mutation in cadherin-like and PC-esterase domain containing 1 (*CPED1*) gene is the only one which survived our stringent variant filtering criteria, as detailed in our methods. Interim release of UK Biobank data (UKBB) on gene-phenotype association reported a number of *CPED1* variants are significantly associated with gastrointestinal clinical phenotypes ([@b0265], [@b0155]). The putative CD causal variant of *CPED1* gene is found in homozygous condition in both siblings, whereas it was seen in heterozygous condition in parents.Table 1List of homozygous nucleotide variants which showed autosomal recessive inheritance pattern in CD family.No.Gene nameChromosomal positionRef/Alt BasesEffectHGVS.cHGVS.pdbSNP ID1000GExAC1HEBP112: 13,000,192C/CGGCGGCAGGGCGGCAG5′ UTR variantc.-94\_-79dupCTGCCGCCCTGCCGCC.rs71064363..2NFATC118: 79,400,367C/CGCCCCG5′ UTR variantc.-14\_-9dupCGGCCC.rs749710747..3CPED17: 120,989,862A/GMissense variantc.241A \> Gp.T81Ars1170470130.00110.0011Table 2List of compound heterozygous nucleotide variants following autosomal recessive inheritance pattern in CD family.No.Gene nameChromosomal positionRef/Alt BasesEffectHGVS.cHGVS.pdbSNP ID1000GExAC1CYP27B112: 57,766,052G/CMissense variantc.341C \> Gp.T114Rrs1247839240..CYP27B112: 57,766,119C/TMissense variantc.274G \> Ap.A92Trs958027919..2HIF1A14--61,697,832A/AT5′ UTR variantc.-9dupT.rs769491528..HIF1A14--61,738,090C/TMissense variantc.1325C \> Tp.T442Irs415080500.00390.00363SMAD418: 51,082,732G/GT3′ UTR variantc.\*4277dupT.rs559471969..SMAD418:51,084,012G/GCACA3′ UTR variantc.\*5574\_\*5577dupCACA.rs1491420266..4MUC1619: 8,888,826T/TCCGAFrameshift variantc.40672_40673insTCGGp.K13558fsrs769228524..MUC1619: 8,974,159GA/GFrameshift variantc.6979delTp.S2327fsrs759867982;rs208917..MUC1619: 8,974,184T/CMissense variantc.6955A \> Gp.I2319Vrs200019597;rs208918.0.00035FCGBP19: 39,886,005T/GMissense variantc.8174A \> Cp.N2725Trs2916067.0.00005FCGBP19: 39,902,423C/TMissense variantc.4405G \> Ap.G1469Rrs143680639.0.07386SLC7A422: 21,029,052C/T3′ UTR variantc.\*3G \> A.rs1408094960.0023.SLC7A422: 21,031,031G/TMissense variantc.782C \> Ap.A261D\...

This homozygous nucleotide variant c. 241A \> G (rs117047013), results in the substitution of novel Threonine amino acid at 81st residue position to Alanine. This mutation appeared to have an allele frequency of 0.02985 (\~2%) among 2379 in Saudi Arabia people, whereas only one individual had a homozygous genotype (1/2379 = 0.0004). In the 1000 genome project, allele frequency was reported to be 0.1% with only one homozygous individual. Moreover, in gnomAD, which hosts the genetic data of \~ 251 K individuals from across the world, the frequency of this variant is 0.1%. Hence, the rare frequency of this variant highly suggests it to be a pathogenic and has a potential role in pathophysiology of CD.

3.3. Validation of family specific variant using Sanger sequencing {#s0060}
------------------------------------------------------------------

Sanger sequencing has confirmed that both affected sisters (III.1 and III.2) were homozygous for the mutation c.241A \> G (GG genotype), while both parents (II.1 and II.2) were heterozygous carriers (AG genotype), and that this variant was inherited in the family in an autosomal recessive fashion. This variant was confirmed to be absent in 98% of Saudi CD sporadic cases whereas the remaining 2% were found to be carriers for the heterozygous mutation, confirming the unique familial segregation of this variant, showing a strong association of *CPED1* gene to be the causative in celiac disease.

3.4. Computational analysis of *CPED1* mutant and wild type gene products {#s0065}
-------------------------------------------------------------------------

Cross-species alignment of *CPED1* nucleotide sequences showed that this variant site falls in a highly conserved region ([Fig. 4](#f0020){ref-type="fig"}), further confirming our initial suspicion that this variant is pathogenic. Additionally, amino acid sequence analysis too confirmed the high-level conservation of the residue and its location across nine primates, indicating its critical role to the function of *CPED1* protein.Fig. 4(A) Phylogenetic tree of the human Cadherin-like and PC-esterase domain containing 1 (*CPED1*) aligned with 13 primates showing the aligned sequence in dark blue sections and gaps in white sections. (B) Nucleotide sequence Alignment of human and primates *CPED1* gene showing the highly conservative site of *CPED1* variant. (C) Alignment region containing *CPED1* variant in chromosome 7.

While an open reading frame for *CPED1* gene has been defined, but its protein structure at three-dimensional level has not been solved through conventional x-ray crystallography methods. Therefore, we have adopted an *ab-initio* modeling approach using I-TASSER that uses only the highest significance in the string alignments to obtain *CPED1* protein model. The predicted *CPED1* protein model had the C-score of −1.16, TM-score of 0.57 ± 0.15 and RMSD score of 11.8 ± 4.5 Å. Overall, these scores indicate the high quality of the predicted structure and accurate folding of *CPED1* protein chains. Furthermore, superimposition at the protein residue level revealed significant divergence of *CPED1* protein in mutant condition (RMSD score is 1.8735 Å), ([Fig. 5](#f0025){ref-type="fig"}).Fig. 5Molecular view of protein superimposition of native (green in color) and mutant (blue in color) version of *CPED1* proteins.

DUET-Integrated computational approach (ΔΔG) of the two methods (mCSM and SDM) that uses SVM regression with a Radial Basis Function kernel has predicted that the p.Thr81Ala substitution destabilizes the *CPED1* protein (ΔΔG is −0.562 Kcal/mol). Furthermore, protein--protein interaction network analysis showed the functional association of *CPED1* with ten protein partners, of which Wnt family member 16 (WNT16) and Protein Phosphatase 6 Regulatory subunit 3 (PPP6R3) proteins had the highest confidence scores of 0.61 and 0.57, respectively ([Fig. 6](#f0030){ref-type="fig"}).Fig. 6Predicted interactions in protein network analysis for *CPED1* (red colored node) were exported from STRING online database (<http://string-db.org>). Circled protein nodes indicate the strongest protein partners for *CPED1* protein.

4. Discussion {#s0070}
=============

HLA loci, spanning several genes and variants by and large is the major known genetic risk factor contributing to the development of CD ([@b0005]). In quest of solving the non-HLA genetic basis of CD, several GWAS studies with case-control study design were conducted in several ethnic populations. However, most studies have reported the association of genetic variants which could explain disease risk only for the specific ethnic population. First GWAS was conducted with 778CD cases and 1422 controls revealed a genetic variant (rs13119723) in a linkage disequilibrium block encompassing the KIAA1109/Tenr/IL2/IL21 genes, as a novel susceptibility factor for CD among British population ([@b0295]). Later on, the list of potential CD risk variants was further expanded with *CCR3*, *IL12A*, *IL18RAP*, *RGS1*, *SH2B3* and *TAGAP* genes which regulates immune reactions in humans ([@b0145]). GWAS has so far identified 57 risk loci spanning multiple genes like *PTPN2*, *IL18RAP*, *CCR4*, *ICOSLG*, *TAGAP*, *DUSP10*, *PUS10*, etc. ([@b0080], [@b0105], [@b0120], [@b0135], [@b0140], [@b0235], [@b0280], [@b0330]). However, these GWAS studies have been conducted on patients of European and American ethnicity, leaving a gap of knowledge on CD from Arab population, which has high inbreeding rate ([@b0035], [@b0050]). Single case-control study reported from Saudi Arabia had described that a 518 Thr/Thr polymorphism in *MMEL1* had an independent association with susceptibility to CD in Saudi patients ([@b0250]). However, all the above studies only highlighted statistically associated common variants but not the specific causal factors of CD etiology.

On the contrary, WES has created a paradigm shift in genetic diagnosis of complex diseases, which are otherwise very difficult to be exclusively studied by conventional Sanger sequencing ([@b0175], [@b0200]). Extending the power of WES and deep resequencing, a large cohort of large families with many affected members of Caucasian origin was unable to identify any new CD mutations ([@b0230]). Moreover, a recent study on a Saudi family found the putative protective role of a rare homozygous insertion (c.1683_1684insATT) in AK5 gene which modifies the risk of Saudi population against CD development ([@b0025]). However, with the recent availability of Saudi Human Genome Project (SHGP) data, it is now feasible to find the true positive disease causative genes ([@b0030], [@b0320]).

Here, by using WES, a hypothesis free survey to scan potential coding rare variants, we identified a rare *CPED1* genetic mutation (c. 241A \> G). Remarkably, this novel variant has not been previously associated with any disease. This study is the first to propose *CPED1* as a causative gene of CD in a Saudi family. This gene is located on the long arm of chromosome 7 at the position of 31.31. It is composed of 3081 nucleotides, 23 exons and encodes a 1,026 amino acid long protein ([@b0335]). This protein comprises an N-terminal signal peptide that functions in the guidance of the protein product to the secretory pathway. It consist of two domains mainly involved in acyl-transferase and acyl-esterase activities for the modification of glycoproteins, a cadherin-like domain, and a PC esterase domain with an N-terminal fused ATP-grasp domain ([@b0055]). Our *in-silico* analysis showed a decreased stability of the assembly of these two domains which may affect the protein integrity and might also contribute to CD.

Moreover, genetic background of CD has been reported to share a common susceptibility risk-loci with other immune diseases like inflammatory bowel disease and rheumatoid arthritis. Meta-analysis of GWAS data has reported four shared risk loci in *PUS10*, *PTPN2*, *TAGAP*, and *IL18RAP* between CD and Crohn's disease due to their common genetic pathway ([@b0105]), and seven shared loci with rheumatoid arthritis (Alexandra Zhernakova et al., 2011) counting on the shared mechanism between the two diseases in antigen presentation and T-cell activation. Furthermore, a cross‐disease study based on gene expression showed the upregulation of *FASLG*, *PLEK*, *CCR4*, and *TAGAP* genes in both CD and ulcerative colitis ([@b0225]). Overall, our results show a similar correlation that links *CPED1* as a CD causal gene based on the genome wide association studies in UKBB with inflammatory bowel disease, rheumatoid arthritis and multiple intestinal diseases (Supplementary table 2). Moreover, GWAS among 3,475 Finnish ancestry individuals, found the association of intronic *CPED1* variant (rs77670845) with alterations in plasma interleukin 2 levels (IL-2) ([@b0020]). Interleukin 2 has an important role in immune system especially in the autoimmune disease prevention, where IL-2 promotes the differentiation of particular immature T-cells into regulatory T-cells, which suppress other T-cells that are otherwise primed to attack normal healthy cells in the body ([@b0325]). The role of IL-2 in immunity reportedly to act against gluten consumption in CD patients ([@b0290]) suggesting the use of IL-2 high serum level as a reliable diagnostic approach in celiac patients ([@b0125]).

Because *CPED1* is a novel candidate gene with largely unknown functions, *CPED1* mutations are few and limited to 20 citations in PubMed. Data from Human Protein Atlas ([[https://www.proteinatlas.org/]{.ul}](https://www.proteinatlas.org/){#ir020}) indicate that *CPED1* is expressed in several tissues and most abundant in the gastrointestinal mucosa. Likewise, *CPED1* expressed in myeloid dendritic cells (DC), plasmacytoid DC, intermediate monocyte, classical monocyte and non-classical monocyte. Protein network predictions of *CPED1* has linked it to the protein PPP6R3, which is known for its important role in maintaining immune self-tolerance ([@b0070]). Another predicted protein--protein association was on *CPED1* with WNT16 protein. WNT signaling has a fundamental role in cellular development, proliferation and cell fate regulation ([@b0190]). WNT signaling is important for the intestinal cells' proliferation, gut development ([@b0130]) and alteration in such signaling pathways can affect the intestinal epithelial proliferation as it is expressed early in human infants ([@b0085]). This suggests a therapeutic potential as it activates the WNT signaling to compromise the intestinal epithelia in IBD and CD patients ([@b0170]). WNT16 activates the β-catenin/T-cell factor (TCF) pathway in dendritic cells. Recent studies have reported that the activation of Wnt/β-catenin pathway in DCs plays to solve a crucial puzzle in the mucosal tolerance and the suppression of chronic autoimmune pathologies ([@b0270]). Emerging evidence support our hypothesis that mutations in *CPED1* gene may alter the WNT signaling in DCs of the intestinal epithelium, hence it most likely contributes to the celiac pathogenesis.

Human GWAS have repeatedly mapped the uncharacterized *CPED1* gene to the bone mineral density (BMD) phenotypes and with osteoporosis development ([@b0065], [@b0095], [@b0215], [@b0220]). These findings may also explain the short stature phenotype in our patients and the growth failure in Saudi CD patients ([@b0245]). Shifting from genetic causes to environmental factors, one study showed how cesarean delivery can play a crucial role on developing CD by influencing the mucosal immune system through the infant's microbiome ([@b0075]). Although more recent studies have reported otherwise ([@b0090], [@b0160]), we found both affected individuals in this family were born by cesarean section.

There are few limitations to which this study would sincerely like to admit. First, the affected sisters have no other sibling to compare the inheritance pattern of variant and also the negative family history to CD. Secondly, *CPED1* has unknown function, making the *in-silico* analysis more challenging to support our claim.

In conclusion, we showed how WES method can be used as a powerful genetic strategy in resolving the molecular basis of complex or polygenic diseases like CD and also presents an opportunity to discover new potential candidate genes and therapeutic targets helpful in disease diagnosis and treatment. Our WES analysis has identified a genetic missense variant in *CPED1* gene c.(241A \> G) as a novel causal gene for CD in a Saudi family. This study expands the spectrum of celiac mutations that could be useful to the genetic diagnosis and counseling of families with CD. It is important to point out the importance of cell line based functional studies from gastrointestinal system to confirm the specific molecular mechanisms through which CPED1 mutations contributes to the biological pathways connected to CD.
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